Effect of anti-tuberculosis drugs on hematological profiles of tuberculosis patients attending at University of Gondar Hospital, Northwest Ethiopia

详细信息    查看全文

• 作者：Eyuel Kassa ; Bamlaku Enawgaw ; Aschalew Gelaw ; Baye Gelaw
• 关键词：Tuberculosis ; Haematological profile ; Intensive phase ; Anti ; TB drugs
• 刊名：BMC Hematology
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：16
• 期：1
• 全文大小：312 KB
• 参考文献：1.World Health Organization. Global tuberculosis control: WHO report 2010. Geneva, Switzerland: WHO; 2010.
  2.Federal Ministry of Health Ethiopia. Tuberculosis, leprosy and TB/HIV prevention and control programme manual. 4th ed. Addis Ababa: MOH; 2008.
  3.World Health Organization. WHO declares TB an emergency in Africa. Call for urgent and extraordinary actions to halt a worsening epidemic. Geneva, Switzerland: WHO; 2005.
  4.World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2008; No. 393. Geneva, Switzerland: WHO; 2008.
  5.World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2007. Geneva, Switzerland: WHO; 2007.
  6.Loulergue P, Mir O, Dhote R. Pure red blood cell aplasia and isoniazid use. Emerg Infect Dis. 2007;13(9):1427.PubMed PubMedCentral CrossRef
  7.Agarwal AK, Chugh IM, Panjabi C, Dewan S, Shah A. Asymptomatic aplastic anaemia in a patient receiving anti-tuberculosis treatment. Indian J Tuberc. 2001;48(2):97–100.
  8.Mintzer DM, Billet SN, Chmielewski L. Drug-induced hematologic syndromes. Adv. Hematol. 2009;2009:495863. doi:10.​1155/​2009/​495863 .
  9.Whitfield CL. Hematologic abnormalities in tuberculous patients. Arch Intern Med. 1970;126(4):698.PubMed CrossRef
  10.Nagayama N, Shishido Y, Masuda K, Baba M, Tamura A, Nagai H, et al. Leukopenia due to anti-tuberculous chemotherapy including rifampicin and isoniazid. Kekkaku: [Tuberculosis]. 2004;79(5):341–8.
  11.Muzaffar TM, Shaifuzain AR, Imran Y, Haslina MN. Hematological changes in tuberculous spondylitis patients at the Hospital Universiti Sains Malaysia. Southeast Asian J Trop Med Public Health. 2008;39(4):686–9.PubMed
  12.Yaranal PJ, Umashankar T, Harish SG. Hematological profile in pulmonary tuberculosis. Int J Health Rehabil Sci. 2013;2(1):50–5.
  13.Maartens G, Willcox PA, Benatar SR. Miliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults. Am J Med. 1990;89(3):291–6.PubMed CrossRef
  14.Olaniyi J, Aken'Ova Y. Haematological profile of patients with pulmonary tuberculosis in Ibadan, Nigeria. Afr J Med Med Sci. 2003;32(3):239–42.PubMed
  15.Koju D, Rao B, Shrestha B, Shakya R, Makaju R. Occurrence of side effects from anti-tuberculosis drugs in urban Nepalese population under DOTS treatment. Kathmandu University J Sci Eng Technol. 2005;1(1):1–2.
  16.Oyer RA, Schlossberg D. Hematologic changes in tuberculosis. In: Schlossberg D, editor. Tuberculosis & Nontuberculous Mycobacterial infections. 5th ed. New Delhi: Tata McGraw-Hill; 2007. pp. 357–64.
  17.Tsegaye A, Messele T, Tilahun T, Hailu E, Sahlu T, Doorly R, et al. Immunohematological reference ranges for adult Ethiopians. Clin Diagn Lab Immunol. 1999;6(3):410–4.PubMed PubMedCentral
  18.Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev. 2002;16(2):87–96.PubMed CrossRef
  19.Baynes R, Flax H, Bothwell T, Bezwoda W, Atkinson P, Mendelow B. Red blood cell distribution width in the anemia secondary to tuberculosis. Am J Clin Pathol. 1986;85(2):226–9.PubMed
  20.Lee SW, Kang Y, Yoon YS, Um S-W, Lee SM, Yoo C-G, et al. The prevalence and evolution of anemia associated with tuberculosis. J Korean Med Sci. 2006;21(6):1028–32.PubMed PubMedCentral CrossRef
  21.Berkowitz FE. Hemolysis and infection: categories and mechanisms of their interrelationship. Review of Infectious Diseases. 1991;13(6):1151–62.CrossRef
  22.Means Jr RT. Recent developments in the anemia of chronic disease. Curr Hematol Rep. 2003;2(2):116–21.PubMed
  23.Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Investig. 2004;113(9):1271.PubMed PubMedCentral CrossRef
  24.Singh K, Ahulwalia G, Sharma S, Saxena R, Chaudhary V, Anant M. Significance of haematological manifestations in patients with tuberculosis. J Assoc Physicians India. 2001;49(788):790–4.
  25.Bhatt V, Saleem A. Drug-induced neutropenia–pathophysiology, clinical features, and management. Ann Clin Lab Sci. 2004;34(2):131–7.PubMed
  26.Nagu TJ, Spiegelman D, Hertzmark E, Aboud S, Makani J, Matee MI, et al. Anemia at the initiation of tuberculosis therapy is associated with delayed sputum conversion among pulmonary tuberculosis patients in Dar-es-Salaam, Tanzania. PLoS One. 2014;9(3), e91229.PubMed PubMedCentral CrossRef
  27.Bougie DW, Wilker PR, Aster RH. Patients with quinine-induced immune thrombocytopenia have both drug-dependent and drug-specific antibodies. Blood. 2006;108(3):922–7.PubMed PubMedCentral CrossRef
  28.Von Drygalski A, Curtis BR, Bougie DW, McFarland JG, Ahl S, Limbu I, et al. Vancomycin-induced immune thrombocytopenia. N Engl J Med. 2007;356(9):904–10.CrossRef
  29.Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357(6):580–7.PubMed CrossRef
  30.Visentin GP, Liu CY. Drug-induced thrombocytopenia. Hematol Oncol Clin North Am. 2007;21(4):685–96.PubMed PubMedCentral CrossRef
  31.Baynes R, Flax H, Bothwell T, Bezwoda W, MacPhail A, Atkinson P, et al. Haematological and iron‐related measurements in active pulmonary tuberculosis. Scand J Haematol. 1986;36(3):280–7.PubMed CrossRef
  32.Morris CD, Bird AR, Nell H. The haematological and biochemical changes in severe pulmonary tuberculosis. QJM. 1989;73(3):1151–9.PubMed
  33.Lombard E, Mansvelt E. Haematological changes associated with miliary tuberculosis of the bone marrow. Tuber Lung Dis. 1993;74(2):131–5.PubMed CrossRef
  34.Dosumu E. Pattern of some haematological indices in newly diagnosed pulmonary tuberculosis cases in Iwo, Nigeria: diagnostic and therapeutic implications. Niger J Med. 2000;10(1):18–20.
  35.Vajpayee N, Graham S, Bem S. Basic examination of blood and bone marrow. In: McPherson RA, Pincus MR, editors. Henry’s clinical diagnosis and management by laboratory methods. 22nd ed. Philadelphia, PA: Elsevier/Saunders; 2011. p. 30.
  36.Subhashree A, Parameaswari P, Shanthi B, Revathy C, Parijatham B. The reference intervals for the haematological parameters in healthy adult population of chennai, southern India. J Clin Diagn Res. 2012;6(10):1675–80.
  37.Pascual-Figal DA, Bonaque JC, Manzano-Fernández S, Fernández A, Garrido IP, Pastor-Perez F, et al. Red blood cell distribution width predicts new-onset anemia in heart failure patients. Int J Cardiol. 2012;160(3):196–200.PubMed CrossRef
  38.Bessman J, Gilmer Jr P, Gardner FH. Improved classification of anemias by MCV and RDW. Am J Clin Pathol. 1983;80(3):322–6.PubMed
  39.Abdelrahman EG, Gasim GI, Musa IR, Elbashir LM, Adam I. Red blood cell distribution width and iron deficiency anemia among pregnant Sudanese women. Diagn Pathol. 2012;7(168):1596–7.
  40.Rieder HL. Intervention for tuberculosis control and elimination. Paris, International Union Against Tuberculosis and Lung Disease, 2002:pp.554. https://​books.​google.​com.​et/​books?​isbn=​1444113542 .
  41.Osselaer J-C, Jamart J, Scheiff J-M. Platelet distribution width for differential diagnosis of thrombocytosis. Clin Chem. 1997;43(6):1072–6.PubMed
  42.Tozkoparan E, Deniz O, Ucar E, Bilgic H, Ekiz K. Changes in platelet count and indices in pulmonary tuberculosis. Clin Chem Lab Med. 2007;45(8):1009–13.PubMed CrossRef
  43.Yakar F, Yildiz N, Yakar A, Kılıçaslan Z. Isoniazid-and rifampicin-induced thrombocytopenia. Multidiscip Respir Med. 2013;8(1):13.PubMed PubMedCentral CrossRef
  44.George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998;129(11):886–90.PubMed CrossRef
  45.Sahin F, Yazar E, Yıldız P. Prominent features of platelet count, plateletcrit, mean platelet volume and platelet distribution width in pulmonary tuberculosis. Multidiscip Respir Med. 2012;7(1):38.PubMed PubMedCentral CrossRef
  
• 作者单位：Eyuel Kassa (1)
  Bamlaku Enawgaw (1)
  Aschalew Gelaw (2)
  Baye Gelaw (2)
  
  1. Department of Hematology and Immunohematology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences (CMHS), University of Gondar (UOG), Gondar, Ethiopia
  2. Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia
  
• 刊物主题：Hematology; Angiology; Blood Transfusion Medicine; Cancer Research; Human Genetics; Internal Medicine;
• 出版者：BioMed Central
• ISSN：2052-1839

文摘

Background Tuberculosis (TB) treatment may present significant hematological disorder and some anti-TB drugs also have serious side effects. Although many other diseases may be reflected by the blood and its constituents, the abnormalities of red cells, white cells, platelets, and clotting factors are considered to be primary hematologic disorder as a result of tuberculosis treatment. The aim of this study was to determine hematological profiles of TB patients before and after intensive phase treatment.